Network Modularity in Breast Cancer Molecular Subtypes.

Breast cancer is a heterogeneous and complex disease, a clear manifestation of this is its classification into different molecular subtypes. On the other hand, gene transcriptional networks may exhibit different modular structures that can be related to known biological processes. Thus, modular structures in transcriptional networks may be seen as manifestations of regulatory structures that tightly controls biological processes. In this work, we identify modular structures on gene transcriptional networks previously inferred from microarray data of molecular subtypes of breast cancer: luminal A, luminal B, basal, and HER2-enriched. We analyzed the modules (communities) found in each network to identify particular biological functions (described in the Gene Ontology database) associated to them. We further explored these modules and their associated functions to identify common and unique features that could allow a better level of description of breast cancer, particularly in the basal-like subtype, the most aggressive and poor prognosis manifestation. Our findings related to the immune system and a decrease in cell death-related processes in basal subtype could help to understand it and design strategies for its treatment.

Analyzing gene expression profiles in dilated cardiomyopathy via bioinformatics methods

Dilated cardiomyopathy (DCM) is characterized by ventricular dilatation, and it is a common cause of heart failure and cardiac transplantation. This study aimed to explore potential DCM-related genes and their underlying regulatory mechanism using methods of bioinformatics. The gene expression profiles of GSE3586 were downloaded from Gene Expression Omnibus database, including 15 normal samples and 13 DCM samples. The differentially expressed genes (DEGs) were identified between normal and DCM samples using Limma package in R language. Pathway enrichment analysis of DEGs was then performed. Meanwhile, the potential transcription factors (TFs) and microRNAs (miRNAs) of these DEGs were predicted based on their binding sequences. In addition, DEGs were mapped to the cMap database to find the potential small molecule drugs. A total of 4777 genes were identified as DEGs by comparing gene expression profiles between DCM and control samples. DEGs were significantly enriched in 26 pathways, such as lymphocyte TarBase pathway and androgen receptor signaling pathway. Furthermore, potential TFs (SP1, LEF1, and NFAT) were identified, as well as potential miRNAs (miR-9, miR-200 family, and miR-30 family). Additionally, small molecules like isoflupredone and trihexyphenidyl were found to be potential therapeutic drugs for DCM. The identified DEGs (PRSS12 and FOXG1), potential TFs, as well as potential miRNAs, might be involved in DCM.